Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
J Gastrointestin Liver Dis ; 31(1): 31-39, 2022 03 19.
Artigo em Inglês | MEDLINE | ID: mdl-35306559

RESUMO

BACKGROUND AND AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed to replace the concept of non-alcoholic fatty liver disease (NAFLD). The relationship between MAFLD and breast lesions has not been reported. Therefore, we aimed to explore their prevalence and relationship among general population. METHODS: This cross-sectional study was conducted in the First Affiliated Hospital of Chongqing Medical University. After considering the exclusion criteria, 46,547 consecutive women who synchronously accepted breast and abdominal ultrasonography during one physical check-up between January 2015 and September 2018 were enrolled in this study. Prevalence of breast masses (BM), BI-RADS categories breast lesions and MAFLD in general population were revealed and the association between MAFLD and breast mass, BI-RADS categories breast lesions was analyzed by conducting logistic regression models. RESULTS: Of 46,547 participants, 8,020 (17.23%) had BM, 6,345 (13.63%) had MAFLD. Women with MAFLD had a lower BM prevalence than those without MAFLD (11.87% vs.18.08%; p<0.001). Overall, women with MAFLD had a lower risk of BM compared to those without MAFLD (adjusted OR=0.849, 95%CI: 0.775-0.930, p<0.001). Analysis based on BI-RADS categories breast lesions demonstrated that MAFLD is negatively related to BI-RADS 2/3 categories breast lesions (BI-RADS 2 category adjusted OR=0.980, 95%CI: 0.906-1.061, p=0.626; BI-RADS 3 category adjusted OR=0.736, 95%CI: 0.641-0.845, p=0.001), while associated with higher risk of BI-RADS ≥4 categories breast lesions (adjusted OR=1.220, 95%CI: 1.005-1.480, p=0.044). Subgroup analysis across age (18-44, 45-54 and≥55 years old) and body mass index (<25 and ≥25kg/m2) demonstrated that MAFLD was negatively associated with BI-RADS 2/3 categories breast lesions in premenopausal and perimenopausal women, and positively associated with BI-RADS ≥4 categories breast lesions in postmenopausal women, whether in obese or not. CONCLUSIONS: MAFLD was inversely associated with BM and BI-RADS 2/3 categories breast lesions in premenopausal and perimenopausal women, irrespective of obesity presence; MAFLD increased the risk of BM and BI-RADS ≥4 categories breast lesions in postmenopausal women.


Assuntos
Neoplasias da Mama , Hepatopatia Gordurosa não Alcoólica , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/epidemiologia , China/epidemiologia , Estudos Transversais , Feminino , Humanos , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/diagnóstico por imagem , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Hepatopatia Gordurosa não Alcoólica/metabolismo , Obesidade , Prevalência
2.
Int J Med Sci ; 18(14): 3082-3089, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34400878

RESUMO

Objectives: To determine the relationship between the endometrial thickness (ET) and metabolic associated fatty liver disease (MAFLD) in the postmenopausal women who have a comprehensive health examination. Methods: This was a population-based, retrospective observational study of the prevalence of MAFLD in 8594 postmenopausal women with different ET in the Quality Control Center of Health Examination in Chongqing, China. Binary and multivariable logistic regression analyses were used to obtain odds ratios and 95% confidence intervals for patients of different ET with MAFLD after adjusting for age. Results: The incidences of MAFLD were 28.6% (1352), 30.3% (1058), 34.9% (133) in postmenopausal women with ET of < 3 mm, 3 mm ≤ & < 5 mm, and ≥ 5 mm, respectively. Compared with a baseline ET of less than 5.0 mm, the risk of MAFLD in patients with ET of ≥5.0 mm is higher (OR=1.291, 95% CI: 1.041-1.603, P<0.05). After adjustment for age, a statistically significant positive correlation was still observed. The increased prevalence of MAFLD in patients with ET of 3 mm ≤ &<5 mm (OR=1.110, 95% CI: 1.008-1.223) and ≥5 mm (OR=1.383, 95% CI: 1.109-1.724) achieved statistical significance, respectively. In addition, multiple logistic analyses controlling for age also confirmed the finding of positive correlation among body mass index (BMI) and ET. Conclusion: Our results suggest that there is a positive correlation between MAFLD and ET in postmenopausal women. In addition, increased BMI is also associated with an increased risk of thickened endometrium.


Assuntos
Endométrio/diagnóstico por imagem , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Pós-Menopausa , Idoso , Doenças Assintomáticas/epidemiologia , Índice de Massa Corporal , China/epidemiologia , Estudos Transversais , Endométrio/anatomia & histologia , Feminino , Humanos , Incidência , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/diagnóstico , Hepatopatia Gordurosa não Alcoólica/metabolismo , Prevalência , Estudos Retrospectivos , Ultrassonografia
3.
BMC Gastroenterol ; 21(1): 212, 2021 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-33971822

RESUMO

BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a new definition for liver disease associated with known metabolic dysfunction. Based on new diagnostic criteria, we aimed to investigate its prevalence and risk factors in Chinese population. METHODS: We conducted this study in a health examination population who underwent abdominal ultrasonography in China. The diagnosis of MAFLD was based on the new diagnostic criteria. The characteristics of the MAFLD population, as well as the associations between MAFLD and metabolic abnormalities, were explored. Mann-Whitney U test and chi-square test were performed to compare different variables. Binary logistic regression was used to determine the risk factors for MAFLD. RESULTS: Among 139,170 subjects, the prevalence of MAFLD was 26.1% (males: 35.4%; females: 14.1%). The prevalence based on female menopausal status, that is, premenopausal, perimenopausal, and postmenopausal, was 6.1%, 16.8%, and 30.2%, respectively. In different BMI groups (underweight, normal, overweight and obese), the prevalence was 0.1%, 4.0%, 27.4% and 59.8%, respectively. The proportions of abnormal metabolic features in the MAFLD group were significantly higher than those in the non-MAFLD group, as was the proportion of elevated alanine aminotransferase (ALT) (42.5% vs. 11%, P < 0.001). In nonobese individuals with MAFLD, the proportions of abnormal metabolic features were also all significantly higher than those in nonobese individuals without MAFLD. The prevalence of metabolic syndrome (MS), dyslipidaemia, and hyperuricaemia, respectively, in the MAFLD group (53.2%, 80.0%, and 45.0%) was significantly higher than that in the non-MAFLD group (10.1%, 41.7%, and 16.8%). Logistic regression revealed that age, BMI, waist circumference, ALT, triglycerides, fasting glucose, uric acid and platelet count were associated with MAFLD. CONCLUSIONS: MAFLD is prevalent in China and varies considerably among different age, sex, BMI, and female menopausal status groups. MAFLD is related to metabolic disorders, especially obesity, while metabolic disorders also play important roles in the occurrence of MAFLD in nonobese individuals. MAFLD patients exhibit a high prevalence of MS, dyslipidaemia, hyperuricaemia, and elevated liver enzymes. MAFLD tends to coexist with systemic metabolic disorders, and a deep inner relationship may exist between MAFLD and MS. Metabolic disorders should be considered to improve the management of MAFLD.


Assuntos
Síndrome Metabólica , Hepatopatia Gordurosa não Alcoólica , Índice de Massa Corporal , China/epidemiologia , Estudos Transversais , Feminino , Humanos , Masculino , Síndrome Metabólica/epidemiologia , Hepatopatia Gordurosa não Alcoólica/diagnóstico por imagem , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Prevalência , Fatores de Risco , População Urbana
5.
RSC Adv ; 10(41): 24705-24711, 2020 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-35516209

RESUMO

Spinel oxide NiCo2O4 supported on a three-dimensional hierarchically porous graphene-like carbon (3D HPG) material has been firstly used to enhance the activity of Pt for glycerol electrooxidation. The addition of NiCo2O4 into the Pt/HPG catalyst can significantly improve the catalytic performance for glycerol oxidation. When NiCo2O4 is added to the Pt/HPG catalyst, the onset potential is 25 mV more negative than that on the Pt/HPG catalyst without NiCo2O4. The current density at -0.3 V on the Pt-NiCo2O4 (wt 10 : 1)/HPG electrode is 1.3 times higher than that on the Pt (30 wt%)/HPG electrode. The Pt-NiCo2O4 electrode presented in this work shows great potential as an electrocatalyst for glycerol electrooxidation in an alkaline medium.

6.
Chemosphere ; 216: 684-697, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30391890

RESUMO

Hydrogen-rich water (HRW) has been widely used in research on plant resistance to Cd. However, the underlying molecular mechanism of HRW in ameliorating cadmium stress in vegetables is largely unknown. In this study, the RNA-sequencing analyses were used to characterize the role of HRW in the alleviation of Cd toxicity in Chinese cabbage seedlings. Based on the obtained results, two genes encoding metal ionic transporters, BcIRT1 and BcZIP2 were ultimately selected out. Then, a systematic validation of the metal ion transport function of these two ZIP-encoding genes of pak choi were performed via a yeast transformation system. The results showed that BcIRT1 and BcZIP2 increased the sensitivity of different yeast mutant strains to relative metal ionic stresses and facilitated the accumulation of metal ions (Cd2+, Mn2+, Zn2+, and Fe2+) in yeast; thus, it suggests that BcIRT1 and BcZIP2 probably have the ability to transport Cd2+, Mn2+, Zn2+ and Fe2+ in pak choi. The time-course and concentration-dependent expression profiles of BcIRT1 and BcZIP2 showed that as time with HRW increased, the effectiveness of the repression on the expression of BcIRT1 and BcZIP2 increased, and as the seedlings were exposed to increased Cd concentrations, the inhibition of BcIRT1 and BcZIP2 by HRW was also increased. Over all, these findings provide new insights into the genome-wide transcriptome profiles in pak choi and show that HRW reduced Cd uptake probably through inhibiting the expression of transporters related to Cd absorption, BcIRT1 and BcZIP2.


Assuntos
Brassica/química , Cádmio/química , Proteínas de Membrana Transportadoras/química , Água/química , Transporte Biológico , Perfilação da Expressão Gênica , Água/análise
7.
J Cancer Res Ther ; 14(Supplement): S1076-S1083, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30539849

RESUMO

OBJECTIVE: To systematically review the effect and safety of irinotecan plus cisplatin (IP) compared with etoposide plus cisplatin (EP) in patients with previously untreated extensive-stage small cell lung cancer (E-SCLC). MATERIALS AND METHODS: Databases including PubMed, The Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP, and WanFang Data were searched for the randomized controlled trials (RCTs) about IP compared with EP in patients with previously untreated E-SCLC from the establishment to June 2016. Two reviewers independently screened literature, extracted data and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.3 software (Cochrane Collaboration, Oxford, UK). RESULTS: A total of 12 RCTs involving 2030 patients were finally included. Meta-analysis showed that compared with EP regimen, IP regimen significantly improved the 1- and 2-year survival rates of the patients with previously untreated E-SCLC (risk ratio [RR] = 1.16, 95% confidence interval [CI] [1.03-1.31], P = 0.02; RR = 1.79, 95% CI [1.22-2.61], P = 0.003, respectively). However, there was no significant difference between IP regimen and EP regimen in the objective response rate (ORR) (RR = 1.07, 95% CI [0.99-1.15], P = 0.10) and disease control rate (DCR) (RR = 1.03, 95% CI [0.96-1.10], P = 0.38). The incidence of Grade 3/4 leukopenia, neutropenia, anemia, and thrombocytopenia of IP regimen was sigificantly lower than EP regimen (all P < 0.05), the incidence of Grade 3/4 nausea/vomiting and diarrhea of IP regimen was sigificantly higher than EP regimen (all P < 0.05). CONCLUSION: IP regimen significantly improves the 1- and 2-year survival rates, but not significantly improves the ORR and DCR, compared with EP regimen in patients with previously untreated E-SCLC. IP regimen has less Grade 3 or 4 hematological adverse events. IP regimen is an alternative of EP regimen in patients with previously untreated E-SCLC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Irinotecano/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Cisplatino/uso terapêutico , Diarreia/induzido quimicamente , Diarreia/epidemiologia , Etoposídeo/uso terapêutico , Doenças Hematológicas/induzido quimicamente , Doenças Hematológicas/epidemiologia , Humanos , Incidência , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Náusea/induzido quimicamente , Náusea/epidemiologia , Estadiamento de Neoplasias , Ensaios Clínicos Controlados Aleatórios como Assunto , Carcinoma de Pequenas Células do Pulmão/mortalidade , Carcinoma de Pequenas Células do Pulmão/patologia , Taxa de Sobrevida , Resultado do Tratamento , Vômito/induzido quimicamente , Vômito/epidemiologia
8.
J Cancer Res Ther ; 14(Supplement): S437-S443, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29970703

RESUMO

OBJECTIVE: To systematically review the efficacy and safety of low molecular weight heparin (LMWH) in treating patients with lung cancer received chemotherapy. MATERIALS AND METHODS: Databases including PubMed, The Cochrane Library, Excerpt Medica Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP, and Wanfang Data were searched for the randomized controlled trials (RCTs) about LMWH in treating patients with lung cancer received chemotherapy from the establishment to May 31, 2015. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data, and assessed quality of the included studies. Meta-analysis was then performed by using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) software. RESULTS: A total of eight RCTs involving 952 patients were finally included. Meta-analysis showed that compared with the control group, LMWH significantly improved the 1- and 2-year overall survival (OS) rates of the patients with lung cancer received chemotherapy (risk ratio [RR] =1.65, 95% confidence interval [95% CI] [1.20-2.26], P = 0.002; RR = 2.63, 95% CI [1.40-4.94], P = 0.003, respectively), and significantly reduced the incidence of venous thromboembolism (VTE) (RR = 0.40, 95% CI [0.23-0.69], P = 0.001), not significantly increased the incidence of major bleeding events and thrombocytopenia (RR = 1.29, 95% CI [0.57-2.96], P = 0.54; RR = 0.86, 95% CI [0.69-1.07], P = 0.18, respectively), and not significantly improved the overall response rate (RR = 1.24, 95% CI [0.98-1.57], P = 0.07). CONCLUSION: LMWH improves the 1- and 2-year OS rates of the patients with lung cancer received chemotherapy and reduces the incidence of VTE, not increase the incidence of major bleeding events and thrombocytopenia. These show that there is a certain effect of LMWH, and the security is good.


Assuntos
Fibrinolíticos/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Neoplasias Pulmonares/complicações , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Fibrinolíticos/administração & dosagem , Fibrinolíticos/efeitos adversos , Heparina de Baixo Peso Molecular/administração & dosagem , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Incidência , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/mortalidade , Razão de Chances , Ensaios Clínicos Controlados Aleatórios como Assunto , Análise de Sobrevida , Resultado do Tratamento , Tromboembolia Venosa/epidemiologia , Tromboembolia Venosa/mortalidade
9.
Nan Fang Yi Ke Da Xue Xue Bao ; 38(4): 395-401, 2018 Apr 20.
Artigo em Chinês | MEDLINE | ID: mdl-29735438

RESUMO

OBJECTIVE: To determine whether erythropoietin (EPO) promotes rapid proliferation of glioma through Akt pathway. METHODS: We detected the expression of EPO in human glioma tissues using immunohistochemistry. A nude mouse model bearing human glioma U87 cell xenograft was established and given intraperitoneal injection of EPO or saline every other day, and the tumor growth was observed. In the in vitro experiment, U87 cells were treated with PBS (control), EPO, or EPO with Akt inhibitor, and the expression of p-Akt and cyclin D1 was detected using Western blotting; the cell proliferation rate was determined using cell counting kit-8 and clone formation assay, and the cell cycle changes were analyzed with flow cytometry. RESULTS: Compared with low-grade glioma tissues, high-grade glioma tissues exhibited a significantly increased EPO expression (P=0.0002). In the tumor-bearing mice, EPO treatment significantly increased the expression of EPO (P=0.0006) and p-Akt (P=0.0003) in the tumor and obviously increased the tumor volume (P<0.0001) and weight (P=0.0003). In U87 cells cultured in vitro, EPO treatment obviously accelerated the cell proliferation (P=0.020 on day 3 and 0.028 on day 5), promoted clone formation (P=0.0010), and increased proliferation index (P=0.0028); EPO significantly enhanced the protein expression of p-Akt (P=0.0020) and cyclin D1 (P=0.0022). The application of Akt inhibitor significantly suppressed the effect of EPO in enhancing cyclin D1 and p-Akt expression (both P<0.0001) and promoting cell proliferation. CONCLUSION: EPO can significantly accelerate the proliferation of glioma through Akt pathway.


Assuntos
Neoplasias Encefálicas/patologia , Proliferação de Células/efeitos dos fármacos , Eritropoetina/farmacologia , Glioma/patologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Animais , Linhagem Celular Tumoral , Ciclina D1/metabolismo , Humanos , Camundongos , Camundongos Nus , Transplante de Neoplasias , Transdução de Sinais
10.
Lipids Health Dis ; 17(1): 91, 2018 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-29678178

RESUMO

BACKGROUND: The lipid profile status among breast cancer patients at initial diagnosis and during chemotherapy remain controversial. The aim of this study is to study the status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. METHODS: We conducted a retrospective cohort study of the status of the lipid and lipoprotein in 1054 primarily diagnosed breast cancer patients and 2483 normal controls with age stratification, from July 2015 to October 2016. At the same time, the status of lipid and lipoprotein were also analyzed among 394 breast cancer patients before and after adjuvant chemotherapy. RESULTS: The incidence of dyslipidemia was significantly lower in breast cancer group(42.98%) compared to normal group(58.28%)(P < 0.001). The levels of total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) among breast cancer group were significantly lower compared to normal control group (P < 0.05). With age stratification, the levels of TC and LDL-C in breast cancer group were still significantly lower than those in control group (P < 0.001). And the levels of TC, TG, LDL-C, apolipoprotein B were significantly higher among post chemotherapeutic patients compared to prechemotherapeutic patients, however HDL-C and Apo-A1 levels were contrary. CONCLUSIONS: Breast cancer patients have lower incidence of dyslipidemia compared to normal populations. However, the situation of dyslipidemia may become worsened after chemotherapy. Therefore, lipid monitoring and dyslipidemia prevention and treatment should be conducted for breast cancer patients at initial diagnosis and during chemotherapy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/sangue , Neoplasias da Mama/tratamento farmacológico , Dislipidemias/sangue , Lipoproteínas/sangue , Adulto , Apolipoproteína A-I/sangue , Apolipoproteínas B/sangue , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/patologia , Estudos de Casos e Controles , Quimioterapia Adjuvante/métodos , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Dislipidemias/diagnóstico , Dislipidemias/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Retrospectivos , Fatores de Tempo , Triglicerídeos/sangue
11.
PLoS One ; 12(6): e0179680, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28640902

RESUMO

BACKGROUND: Antiviral drugs have been recommended as prophylaxis for the reactivation of hepatitis B virus (HBV) infection in cancer patients undergoing chemotherapy. However, screening and antiviral prophylaxis for lung cancer remain controversial because of insufficient evidence. PURPOSE: In this study, we investigate the absolute risk for HBV reactivation and the prophylactic effects of antiviral drugs in hepatitis B surface antigen (HBsAg)-positive lung cancer patients during chemotherapy. METHODS: We searched Pubmed, Embase, Cochrane, Web of Science and SinoMed from inception until 28 November 2016, and identified all potential relevant references with or without prophylactic use of antiviral therapy in HBsAg-positive lung cancer patients during chemotherapy. The primary outcome was the incidence of HBV reactivation, the secondary outcomes were the incidence of hepatitis, chemotherapy disruption and mortality. RESULTS: Eleven studies involving 794 patients were analyzed. The incidences of HBV reactivation in control group and antiviral prophylaxis group ranged from 0% to 38% (median, 21%, 95% CI: 0.17-0.25) and 0% to 7% (median, 4%, 95% CI: 0.02-0.06), respectively. Antiviral prophylaxis had significantly reduced the risk for HBV reactivation (RR, 0.22 [95% CI: 0.13-0.37], p< 0.0001), hepatitis (RR, 0.35 [95% CI: 0.22-0.56], p<0.0001) and chemotherapy disruption (RR: 0.29 [95% CI, 0.15-0.55], p<0.0002) compared to those without antiviral prophylaxis. There was no significant heterogeneity in the comparisons, and a fixed-model was used. CONCLUSION: The risks of HBV reactivation and relevant complications are high in HBsAg-positive lung cancer patients receiving chemotherapy, and available evidences support HBV screening for antiviral prophylaxis before initiation of chemotherapy for lung cancer patients.


Assuntos
Antivirais/farmacologia , Vírus da Hepatite B/efeitos dos fármacos , Vírus da Hepatite B/fisiologia , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/virologia , Ativação Viral/efeitos dos fármacos , Hepatite B/prevenção & controle , Humanos , Neoplasias Pulmonares/mortalidade , Risco
12.
Int J Oncol ; 50(3): 815-822, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28112369

RESUMO

HIST1H3D gene encodes histone H3.1 and is involved in gene-silencing and heterochromatin formation. HIST1H3D expression is upregulated in primary gastric cancer tissue. In this study, we explored the effects of HIST1H3D expression on lung cancer, and its mechanisms. HIST1H3D expression was measured by immunohistochemistry and RT-PCR in lung cancer tissues and human lung cancer cell lines. Cell proliferation was assessed by MTT assay. Flow cytometric analysis was used to determine cell cycle distribution and apoptosis. Levels of related proteins were detected by western blotting. Bioinformatics analysis was performed to investigate related signaling pathways. cDNA microarray analysis was performed to identify differentially expressed genes following HIST1H3D knockdown. HIST1H3D expression was upregulated in lung cancer tissue samples and the H1299 human lung cancer cell line (P<0.01). Regulation of HIST1H3D expression in nucleus of cells in lung cancer tissues was significant associated with tumor stage (P=0.02) and lymph node metastases (P=0.04). Downregulation of HIST1H3D expression led to suppression of proliferation and colony forming ability, cell cycle arrest at the G0/G1 phase, and promotion of cell apoptosis. The microarray data revealed 522 genes that were differentially expressed after HIST1H3D knockdown in H1299 cells. These genes were shown to be linked to numerous pathways, including the cell cycle, p53 signaling, and MCM. Western blot analysis confirmed upregulated expression of the THBS1 and TP53I3 genes, and downregulated expression of the CDK6, CDKN1 and CCNE2 genes. In conclusion, our results suggest that HIST1H3D is highly expressed in lung cancer cell lines and tissues. Furthermore, HIST1H3D may be important in cell proliferation, apoptosis and cell cycle progression, and is implicated as a potential therapeutic target for lung cancer.


Assuntos
Apoptose/genética , Ciclo Celular/genética , Proliferação de Células/genética , Histonas/genética , Neoplasias Pulmonares/genética , Células A549 , Linhagem Celular Tumoral , Quinase 6 Dependente de Ciclina/metabolismo , Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Ciclinas/metabolismo , Regulação para Baixo , Feminino , Pontos de Checagem da Fase G1 do Ciclo Celular , Regulação Neoplásica da Expressão Gênica , Histonas/metabolismo , Humanos , Neoplasias Pulmonares/patologia , Metástase Linfática/genética , Masculino , Pessoa de Meia-Idade , Interferência de RNA , RNA Interferente Pequeno/genética , Transdução de Sinais/genética , Trombospondina 1/metabolismo , Proteína Supressora de Tumor p53/metabolismo
13.
Guang Pu Xue Yu Guang Pu Fen Xi ; 35(10): 2810-3, 2015 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-26904823

RESUMO

In the study, CuO/ZnO/Al2O3 was prepared by sol-gel method. Its catalytic activity was evaluated by gas-phase catalytic dehydrogenation of 1, 5-Pentanediol to δ-valerolactone as a probe reaction. CuO/ZnO/Al2O3 and long period reactive CuO/ZnO/Al2O3 were detected by XRD. Micro-structure and essence disciplinarian of CuO/ZnO/Al2O3 were disclosed. Metal ions had a cooperative effects during the catalytic dehydrogenation of 1, 5-pentanediol to δ-valerolactone. After CuO/ZnO/Al2O3 deactivation, crystal particle size was increased clearly. It were found that characteristic diffraction peaks were caused by the catalyst temperature raising in methanol catalytic synthesis of ZnO. 1, 5-Pentanediol and δ-valerolactone were detected by FTIR. Their internal chemical bond and molecular structure were disclosed. The purity of δ-valerolactone product was very high. δ-Valerolactone and its polymer were detected by DSC. δ-Valerolactone possessed with poor stability. Polymerization reaction was easily happened by itself. So it was worth focusing on how to improve the stability of the δ-valerolactone monomer. This study could provide basic data and experimental basis for gas-phase catalytic dehydrogenation of 1, 5-Pentanediol to δ-valerolactone in pilot and industrial scale up research.

14.
Tumour Biol ; 35(9): 9027-33, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24906605

RESUMO

E-cadherin, a tumor repressor gene, has been shown to play an important role in maintaining the polarity and structural integrity of epithelial and is closely associated with tumorigenesis, invasion, and metastasis. The current study aimed to investigate the effects of E-cadherin methylation on lung cancer (LC) quantitatively through a meta-analysis. We searched electronic databases to identify eligible studies from their inception through September 30, 2013. Pooled odds ratio (OR) with 95 % confidence interval (CI) was used to assess the relationship between E-cadherin gene methylation and LC risk. A hazard ratio (HR) with 95 % CI was used to assess the impact of E-cadherin gene methylation on overall survival (OS) of LC patients. Seventeen studies comprising 983 LC cases and 669 controls met the inclusion criteria. Summary results revealed that hypermethylation frequencies in LC tissues were significantly higher than those in normal control tissues (OR = 4.11, 95 % CI 2.78-6.07, P < 0.001). Subgroup analysis indicated that higher methylation frequencies were observed in Asian population. Interestingly, we found that hypermethylation of E-cadherin was associated with significantly better survival with HR of 0.47 (95 % CI 0.31-0.71). This meta-analysis revealed that E-cadherin gene promoter methylation was associated with an increased risk of LC, especially in Asian population, and methylated E-cadherin predicted long survival in patients with LC. However, further studies with large numbers of patients will be needed to confirm the findings.


Assuntos
Caderinas/genética , Metilação de DNA , Neoplasias Pulmonares/genética , Regiões Promotoras Genéticas/genética , Povo Asiático/genética , Humanos , Neoplasias Pulmonares/etnologia , Neoplasias Pulmonares/patologia , Razão de Chances , Fatores de Risco , Análise de Sobrevida
15.
Gene ; 541(2): 69-74, 2014 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-24631267

RESUMO

BACKGROUND: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays a critical role in the development and progression of tumors. Various studies evaluating the prognostic value of HIF-1α in patients with lung cancer (LC) remain controversial. To comprehensively and quantitatively summarize the evidence on the effect of HIF-1α expression on the survival of patients with LC, a meta-analysis was carried out. MATERIAL AND METHODS: Electronic databases were used to identify published studies before August 31st, 2013. Studies were assessed for quality using REMARK. Data were collected comparing overall survival in patients with high HIF-1α expression with those with low expression. RESULTS: Totally, 13 papers including 1420 patients were subjected to final analysis. The combined hazard ratio (HR) was 1.60 (95% CI: 1.14-2.25, P=0.007), suggesting that high expression of HIF-1α was an indicator of poor prognosis. Further, when stratified by LC histological type (SCLC and NSCLC), study region (Asia and Europe), cut-off values (10%), tumor stage (I-III and I-IV), antibody for IHC (H1α67 and ESEE 122), and HR estimated method (univariate/multivariate analysis), most of the results were statistically significant. CONCLUSIONS: Taken together, this meta-analysis revealed that HIF-1α overexpression might be a predicative factor of poor prognosis for NSCLC particularly in Asia.


Assuntos
Biomarcadores Tumorais/metabolismo , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Regulação Neoplásica da Expressão Gênica , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Neoplasias Pulmonares/mortalidade , Anticorpos Antineoplásicos/imunologia , Ásia/epidemiologia , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/imunologia , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Europa (Continente)/epidemiologia , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/metabolismo , Prognóstico , Fatores de Transcrição/metabolismo
16.
Acta Trop ; 130: 67-70, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24141059

RESUMO

Chlamydia spp. are obligate intracellular bacteria distributed globally, known to cause various forms of diseases in animals and humans. To date, there is limited information about the seroprevalence of Chlamydia and the risk factors associated with Chlamydia infection in dogs in the world. In the present study, a serological survey was undertaken to examine the seroprevalence and risk factors associated with dog chlamydiosis in Yunnan Province, southwestern China. A total of 591 dogs were sampled, antibodies to Chlamydia were determined by indirect hemagglutination assay (IHA). The overall seroprevalence was estimated at 17.6%. The risk factors associated with seroprevalence were determined by a multivariate logistic regression analysis. Gender and age of dogs were not significant in the logistic regression analysis (P>0.05) and left out of the final model. Type and geographical origin of dogs were considered as main risk factors associated with Chlamydia infection, stray dogs (31.37%) were more than 16 times (OR=16.167, 95% CI=6.283-41.599, P<0.01) at risk of acquiring the infection compared to the police dogs (7.62%), while pet dogs (14.41%) had a 3 times (OR=2.968, 95% CI=1.349-6.529, P=0.007) higher risk. Positive dogs were found in 5 districts of Yunnan Province with prevalence ranging from 2.56% to 31.67% except Diqing (0/56). Dogs in Kunming (20.21%) had a 9 times higher risk of being seropositive compared to dogs in Lijiang (2.56%) (OR=9.057, 95% CI=1.211-67.714, P=0.032), although no regional differences were found in other 4 administrative divisions compared to Lijiang (P>0.05). Our study revealed a widespread and high prevalence of Chlamydia infection in dogs in Yunnan Province, southwestern China, with higher exposure risk in stray dogs and distinct geographical distribution. These findings suggest the potential importance of dogs in the transmission of zoonotic Chlamydia infection, and thus Chlamydia should be taken into consideration in diagnosing dog diseases.


Assuntos
Infecções por Chlamydia/veterinária , Doenças do Cão/epidemiologia , Animais , Anticorpos Antibacterianos/sangue , China/epidemiologia , Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/etiologia , Estudos Transversais , Doenças do Cão/etiologia , Cães , Feminino , Testes de Hemaglutinação , Humanos , Masculino , Fatores de Risco , Estudos Soroepidemiológicos , Zoonoses/epidemiologia
17.
Zhongguo Zhen Jiu ; 32(8): 721-5, 2012 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-23072095

RESUMO

OBJECTIVE: To observed efficacy differences of acupuncture at "Zusanli" (ST 36) in rats with asthma and asthma with spleen-deficency, so as to investigate the therapeutic mechanism. METHODS: Sixty SD rats were randomly divided into 5 groups according to their weight, named as an asthma with spleen-deficency group (group A), an acupuncture on asthma with spleen-deficency group (group B), an asthma group (group C), an acupuncture on asthma group (group D) and a control group. The rat models with spleen-deficiency in the first two groups were set up by TCM, then the rats of asthma model in the first four groups were induced by egg albumin, but the control group was treated by the same dose of saline. The group B and the group D were both treated with acupuncture at "Zusanli" (ST 36), once each day for 8 days, and the other groups remained unhandled. The mRNA expressions of Fas and Bcl-2 in the lung tissues were detected by hybridization in situ and apoptosis was detected by TUNEL (terminal dexynucleotidyl transferase-mediated dutp nick end labeling). RESULTS: Compared with the control group, in both the group A and the group C, the expression of Fas mRNA significantly decreased, but the expression of Bcl-2 mRNA significantly increased (all P < 0.01), and eosinophils (EOS) counts significantly increased, but EOS apoptosis rate significantly decreased (all P < 0.01). Compared with the group C, in the group A, the expressions of Fas mRNA significantly decreased, but the expressions of Bcl-2 mRNA and EOS counts significantly increased (all P < 0.01). At the same time, compared with the corresponding asthma groups, in both acupuncture groups, Fas mRNA expression obviously increased, Bcl-2 mRNA expression was significantly reduced (all P < 0.01), EOS counts remarkably decreased and EOS apoptosis rate significantly increased (all P < 0.01). There were no significant differences in the expressions of Fas mRNA and Bcl-2 mRNA between the two acupuncture groups (both P > 0.05), but compared with group B,in the group D, EOS counts significantly decreased and EOS apoptosis rate significantly increased (both P < 0.01). CONCLUSION: Acupuncture at "Zusanli" (ST 36) can regulate the disorders of Fas mRNA and Bcl-2 mRNA expression in the state of both asthma and asthma with spleen-deficency, promote EOS apoptosis so as to inhibit the development of inflammatory reaction of asthma, showing that acupuncture at "Zusanli" (ST 36) has certain advantages on regulation of related gene of EOS in asthma with spleen-deficency.


Assuntos
Pontos de Acupuntura , Apoptose , Asma/genética , Asma/terapia , Eosinófilos/citologia , Terapia por Acupuntura , Animais , Asma/imunologia , Asma/fisiopatologia , Eosinófilos/imunologia , Expressão Gênica , Humanos , Masculino , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Receptor fas/genética , Receptor fas/imunologia
18.
Parasit Vectors ; 5: 118, 2012 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-22704457

RESUMO

BACKGROUND: Toxoplasmosis is a zoonotic parasitic disease caused by the protozoan Toxoplasma gondii, which infects almost all warm-blooded animals, including humans, with a worldwide distribution. However, little is known of T. gondii seroprevalence in pet dogs in Kunming, the capital of Yunnan Province, southwest China. The objective of this investigation was to estimate the seroprevalence of T. gondii infection in pet dogs in this area. METHODS: A total of 611 serum samples were collected from 7 pet hospitals in Kunming, and assayed for T. gondii antibodies by the indirect haemagglutination (IHA) using a commercially-marked kit. RESULTS: 132 (21.6%) pet dogs were positive for T. gondii antibodies, and the seroprevalence ranged from 17.3% to 34.7% among different sampling regions, the difference was statistically significant (P < 0.05). The T. gondii seroprevalence in female and male dogs were 20.8% and 22.4%, respectively, the difference was not statistically significant (P > 0.05). The seroprevalence ranged from 17.5% to 23.6% among different age groups, but the difference was not statistically significant (P > 0.05), and there were no interactions in statistics (P > 0.05) between gender and age of pet dogs in the region. CONCLUSIONS: The findings of the present survey indicate high T. gondii seroprevalance in pet dogs in Kunming, southwest China, posing significant public health concern. It is necessary to enhance integrated strategies and measures to prevent and control T. gondii infection in pet dogs in this area.


Assuntos
Doenças do Cão/parasitologia , Animais de Estimação , Toxoplasma , Toxoplasmose Animal/sangue , Animais , Anticorpos Antiprotozoários , China/epidemiologia , Doenças do Cão/epidemiologia , Cães , Feminino , Masculino , Estudos Soroepidemiológicos , Toxoplasmose Animal/epidemiologia
19.
Guang Pu Xue Yu Guang Pu Fen Xi ; 30(8): 2103-6, 2010 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-20939316

RESUMO

The Cu1Zr1Ce9Odelta catalysts synthesized with coprecipitation method were used into the selective CO oxidation in hydrogen-rich gas. The adsorbed species and the intermediates on Cu1Zr1Ce9Odelta catalysts were examined by in-situ diffuse reflectance FTIR spectroscopy (in-situ DRIFTS) technique. It was found that hydrogen, oxygen and CO in the feed stream were adsorbed competitively at the same adsorption sites on the surface of Cu1Zr1Ce9Odelta catalysts. The pretreatment with hydrogen caused the deep reduction of Cu+ species to Cu0 species and decreased the capacity of CO adsorption on the catalyst surface. The Cu1Zr1Ce9Odelta catalyst pretreated with oxygen offered more active oxygen species and inhibited the deep reduction of Cu+ species. The helium pretreatment only purified the surface of Cu1Zr1Ce9Odelta catalyst. Two IR bands at 2938.7 and 2843.8 cm(-1) due to bridged formate and bidentate formate species appeared at 180 degrees C. The active oxygen anion of Cu1Zr1Ce9Odelta catalyst could react with CO and produce carbonate species at room temperatures. The carbonate and formate species occupied the adsorption sites and deteriorated the catalytic performance of Cu1Zr1Ce9Odelta. Flushing the Cu1ZnrCe9Odelta catalyst with helium at 300 degrees C, the bidentate formate species on the catalyst surface decomposed to monodentate carbonate species and then further decomposed to CO2, which could release the adsorption sites and restore well the catalytic activity.

20.
Guang Pu Xue Yu Guang Pu Fen Xi ; 30(3): 672-6, 2010 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-20496684

RESUMO

CuO-CeO2 series catalysts are the effective catalysts for the selective CO oxidation in hydrogen-rich gas. The adsorption species on the CuO-CeO2 catalysts doped with alkali and alkaline earth metal oxides were investigated with in situ diffuse reflectance FTIR spectroscopy (in-situ DRIFTS) technique. The results showed that a bane at 2 106 cm(-1), due to the carbonyl species, appeared on the CuO-CeO2 catalysts. In the reaction atmosphere, the intensity of this band increased first and then decreased with increasing the temperatures. It was noted that the main active adsorption sites of the CuO-CeO2 catalysts were Cu+ species. At lower temperatures, the carbonyl species were desorbed from the surface of CuO-CeO2 catalysts in the reversible form, while they were desorbed mainly in the irreversible form at the higher temperatures. A sharp peak at 3 660 cm(-1), attributed to the geminal Ce(OH)2 group, was also apparent on the surface of reduced CuO-CeO2 catalyst. The peaks at 1 568, 2 838 and 2 948 cm(-1) were attributed to formate species and the peaks centered at 1 257 and 1 633 cm(-1) were assigned to carbonate species. CO could react with the active hydroxyl species and generate formate species. At higher temperatures, the C-H bond of formate species could break and form carbonate species. These two species would decrease the performance of CuO-CeO2 catalysts at higher temperatures. The stronger IR peaks attributed to CO2 and formate species were observed, moreover there was still a weak IR peak assigned to carbonyl species for Cu1 Li1 Ce9Odelta catalyst when the temperature was above 180 degrees C. It was shown that as the electron donor, the doping of Li2 O on CuO-CeO2 catalyst could contribute to the irreversible desorption of CO at lower temperatures and inhibit the adsorption of H2 on the catalytic surface, and benefit the formation of formate species as well. Although the amounts of CO adsorption on Cu1 Mg1 Ce9 Odelta and Cu1 Ba1 Ce9 Odelta catalysts were much more than other catalysts at lower temperatures, they were mainly desorbed in the reversible form, which had no contribution to the selective CO oxidation.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA